Wendy Chen, MD @DanaFarber @harvardmed #ASCOPlenary22 Phase III ABC Trial

Editor

3 years ago

Wendy Chen, MD, MPH, Assistant Professor, Medicine, Harvard Medical School, Senior Physician, Breast Oncology Center, Dana-Farber Cancer Institute. In this video, she speaks about ASCO Plenary 2022 – Abstract 360922: A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial.

Description in detail:

In early-stage node-positive HER2 negative breast cancer patients, this is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily). Hormone Receptor status (HR positive vs HR negative), body mass index (30 vs 30 kg/m2), and stage will all be used to stratify patients (Stage II vs III).

The major goal of this study is to see how aspirin compares to placebo in terms of invasive disease-free survival (iDFS).

The primary goal The goal of this study was to see how aspirin (300 mg daily) compared to placebo affected invasive disease-free survival (iDFS) in patients with early-stage node-positive HER2 negative breast cancer.

Supplementary goals

In early-stage node-positive HER2 negative breast cancer patients, assess the effects of aspirin versus placebo on:

Disease-free survival at a distance

Overall, survival is possible.

Cardiovascular disease (CVD) is a condition that affect (see Section11.3)

The purpose of this study was to examine the toxicity of aspirin with placebo in individuals with early-stage node-positive HER2 negative breast cancer.

The goal of this study was to see how well aspirin and placebo were tolerated by patients with early-stage node-positive HER2 negative breast cancer.

To store tumor and germline deoxyribonucleic acid (DNA), plasma and urine taken at baseline, as well as sequential plasma and urine obtained 2 years later for future inflammatory marker measurements.

To see if there are any subgroups of participants who benefit more from aspirin than placebo on the iDFS because of lifestyle characteristics linked to increased inflammation.

Patients are tracked for up to ten years after enrolling in the trial.